SCHEMBL2106441

SCHEMBL2106441

COC(=O)[C@@H]1C[C@@H](Sc2ccc(F)cc2Cl)CN1C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.44
CCNT1 O60563 1/20 0.42
CDK9 P50750 1/20 0.42
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
PTPN1 P18031 1/20 0.39
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
P2RX3 P56373 2/20 0.36
PDE4B Q07343 1/20 0.36
MMP2 P08253 1/20 0.36
ABL1 P00519 2/20 0.36
BCR P11274 2/20 0.36
ALDH1A1 P00352 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
USP30 Q70CQ3 1/20 0.35
KDM4D Q6B0I6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15169964 0.89 ALDH1A1 (0.41) CTSSNR1H2NR1H3PTPN1CYP1A2
SCHEMBL15184109 0.89 CYP1A2 (0.46) CTSSCCNT1CDK9NR1H2NR1H3
SCHEMBL716249 0.88 CCNT1 (0.40) CTSSCCNT1CDK9NR1H2NR1H3
SCHEMBL696886 0.86 NR1H2 (0.42) CTSSNR1H2NR1H3PTPN1CYP1A2
SCHEMBL14974696 0.86 NR1H2 (0.42) CTSSNR1H2NR1H3PTPN1CYP1A2
SCHEMBL2685355 0.86 NR1H2 (0.42) CTSSNR1H2NR1H3PTPN1CYP1A2
SCHEMBL689919 0.83 P2RX3 (0.43) CTSSNR1H2NR1H3PTPN1CYP1A2
SCHEMBL15194628 0.82 CTSS (0.65) CTSS
SCHEMBL15194287 0.82 CTSS (0.65) CTSS
SCHEMBL697218 0.82 NR1H2 (0.42) NR1H2NR1H3PTPN1CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 CTSS 1542/4885CCNT1 105/4885CDK9 2649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.